P803 A single-centre study on the uptake of cervical cancer screening in patients with inflammatory bowel disease
M. Nwaezeigwe*1, A. Keogh2, L. Egan2
1University Hospital Galway, Galway, Ireland, 2Univeristy Hospital Galway, Galway, Ireland
Researchers have found a higher risk of cervical neoplasia in patients with inflammatory bowel disease, especially those treated with azathioprine. In Ireland, cervical cancer is the second most common cancer in women aged 25–39 years. Screening in Ireland is co-ordinated by CervicalCheck, the national cervical screening programme. ECCO guidelines and several others strongly recommend regular cervical screening for women with IBD, especially if treated with immunomodualtors. Several studies across different populations looking into the IBD population have showed a low-adherence to the recommendation regarding cervical cancer screening. The uptake rates of this screening programme in Irish IBD patients is largely unknown. The aim of this study was to assess the uptake and adherence of IBD patients to the national cervical screening programme(CSP).
This cross-sectional study was conducted from August to November 2018 in the outpatient department at University Hospital Galway. Female patients of cervical screening age (25–60 years) with a known diagnosis of inflammatory bowel disease attending the IBD clinics were recruited. Patients who agreed to participate and gave written consent were given a questionnaire to complete. The questionnaire included demographic data, name of drug therapy, questions regarding cervical smear test uptake, compliance to follow-up, and smear results if known. Ethical approval was granted for this study. Data were analysed using SPSS.
64 patients provided complete information regarding their cervical screening history. These women were relatively young (Mean =41 years, SD= 9.7) 58 (91%) reported enrolment in the CSP. Twenty-one (33%) of these patients had at one time had an irregular smear. Four(6.4%) women had high grade smear changes requiring LETZ procedure. All the women with high-grade changes were in receipt of immunomodulator therapy. The survey identified 48 (75%) women who reported regular follow-up with the CSP.
This cross-sectional study showed that our cohort of women participated in the screening programme at satisfactory levels. However, this number drops in terms of follow-up with the CSP. Patients need ongoing education and encouragement to maintain participation in the CSP. Although this is a single-centre study, and the numbers studied are smaller than that reported in other similar studies, the results provide a glimpse into the prevalence of the uptake of cervical screening among Irish women with IBD.